We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid-derived stem cells for therapeutic applications. Its core activity is stem cell res... Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid-derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues. Show more
Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy...
Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA...
A biotech company that is no stranger to coming across our desk has made headlines yet again after it was announced the company received orphan drug To read the full story on AllPennyStocks.com...
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology...
Creative Medical Technology Holdings Provides Corporate Update PR Newswire PHOENIX, Nov. 15, 2023 Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong...
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic...
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.49 | -10.1871101871 | 4.81 | 4.97 | 4.298 | 19926 | 4.73006408 | CS |
4 | -0.89 | -17.0825335893 | 5.21 | 5.85 | 4.298 | 15894 | 5.18765826 | CS |
12 | 0.09 | 2.12765957447 | 4.23 | 10.2812 | 3.93 | 225340 | 5.80309051 | CS |
26 | -0.31 | -6.69546436285 | 4.63 | 10.2812 | 3.93 | 109760 | 5.74299842 | CS |
52 | -2.28 | -34.5454545455 | 6.6 | 10.2812 | 3.93 | 131303 | 5.72182313 | CS |
156 | -27.68 | -86.5 | 32 | 51.45 | 3.3 | 1354279 | 20.18227806 | CS |
260 | -27.68 | -86.5 | 32 | 51.45 | 3.3 | 1354279 | 20.18227806 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions